An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-8527 in Participants With Mild and Moderate Hepatic Impairment
Latest Information Update: 20 Jun 2025
At a glance
- Drugs MK-8527 (Primary)
- Indications Liver cancer
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 20 Jun 2025 New trial record